Key points are not available for this paper at this time.
Despite predicted and previously reported resistance, osimertinib may have durable efficacy against rare EGFR L747P mutations. Persistent attempts to acquire material for tumor genomic analysis may yield results critically important to clinical management.
Gerber et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: